OncoCyte has appointed Ronald Andrews to its board of directors, bringing its total number of directors to seven and its independent directors to four. Andrews has over 30 years' experience in the molecular diagnostics and genomics industries, and was founder and principal of the Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Prior to founding Bethesda, he served as president of the Genetic Sciences Division at Thermo Fisher Scientific and president of the Medical Sciences Venture at Life Technologies. He was also CEO and segment leader of GE Molecular Diagnostics at Clarient from 2004 until 2012. Andrews currently serves on the board of directors of Insight Genetics, Orion Healthcare, and Oxford Immunotec.
OncoCyte also announced that Cavan Redmond has been appointed as chairman of its board of directors. He will be replacing Alfred Kinglsey, who will remain a director of the firm. Before his time at OncoCyte, Redmond previously served as CEO of WebMD. In addition, he has served as senior VP and group president at Pfizer.